Division of Pediatric Cardiology, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA.
Department of Biostatistics, Emory University, Atlanta, GA, USA.
Cardiol Young. 2021 Oct;31(10):1595-1607. doi: 10.1017/S1047951121000585. Epub 2021 Mar 2.
Although cardiac catheterisation (cath) is the diagnostic test for pulmonary hypertension, it is an invasive procedure. Echocardiography (echo) is commonly used for the non-invasive diagnosis of pulmonary hypertension but maybe limited by lack of adequate signals. Therefore, emphasis has been placed on biomarkers as a potential diagnostic tool. No prior paediatric studies have simultaneously compared N-terminal pro-B-type-natriuretic peptide (NTproBNP) with cath/echo as a potential diagnostic tool. The aim of this study was to determine if NTproBNP was a reliable diagnostic tool for pulmonary hypertension in this population.
Patients were divided into Study (echo evidence/established diagnosis of pulmonary hypertension undergoing cath) and Control (cath for small atrial septal defect/patent ductus arteriosus and endomyocardial biopsy post cardiac transplant) groups. NTproBNP, cath/echo data were obtained.
Thirty-one patients met inclusion criteria (10 Study, 21 Control). Median NTproBNP was significantly higher in the Study group. Echo parameters including transannular plane systolic excursion z scores, pulmonary artery acceleration time and right ventricular fractional area change were lower in the Study group and correlated negatively with NTproBNP. Receiver operation characteristic curve analysis demonstrated NTproBNP > 389 pg/ml was 87% specific for the diagnosis of pulmonary hypertension with the addition of pulmonary artery acceleration time improving the specificity.
NTproBNP may be a valuable adjunctive diagnostic tool for pulmonary hypertension in the paediatric population. Echo measures of transannular plane systolic excursion z score, pulmonary artery acceleration time and right ventricular fractional area change had negative correlations with NTproBNP. The utility of NTproBNP as a screening tool for pulmonary hypertension requires validation in a population with unknown pulmonary hypertension status.
虽然心导管检查(心导管)是肺动脉高压的诊断测试,但它是一种有创性的程序。超声心动图(echo)常用于肺动脉高压的非侵入性诊断,但可能由于信号不足而受到限制。因此,重点已放在生物标志物作为一种潜在的诊断工具上。以前没有儿科研究同时比较 N 端前 B 型利钠肽(NTproBNP)与心导管/超声心动图作为潜在的诊断工具。本研究的目的是确定 NTproBNP 是否是该人群肺动脉高压的可靠诊断工具。
患者分为研究组(超声心动图有肺动脉高压的证据/已确诊,进行心导管检查)和对照组(心导管检查小房间隔缺损/动脉导管未闭和心脏移植后的心肌活检)。获得 NTproBNP、心导管/超声心动图数据。
31 名患者符合纳入标准(10 名研究组,21 名对照组)。研究组的中位 NTproBNP 明显更高。研究组的超声心动图参数,包括跨环平面收缩期位移 z 评分、肺动脉加速时间和右心室分数面积变化较低,与 NTproBNP 呈负相关。受试者工作特征曲线分析表明,NTproBNP>389pg/ml 对肺动脉高压的诊断具有 87%的特异性,加上肺动脉加速时间可提高特异性。
NTproBNP 可能是儿科人群肺动脉高压的有价值的辅助诊断工具。超声心动图测量跨环平面收缩期位移 z 评分、肺动脉加速时间和右心室分数面积变化与 NTproBNP 呈负相关。NTproBNP 作为肺动脉高压筛查工具的效用需要在肺动脉高压状态未知的人群中进行验证。